Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

The 21-gene recurrence score (RS) is prognostic for distant recurrence (DR) and predictive for chemotherapy benefit in early breast cancer, whereas clinical-pathological factors are only prognostic. Integration of genomic and clinical features offers the potential to guide adjuvant chemotherapy use...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparano, Joseph A., Crager, Michael R., Tang, Gong, Gray, Robert J., Stemmer, Salomon M., Shak, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078482/
https://www.ncbi.nlm.nih.gov/pubmed/33306425
http://dx.doi.org/10.1200/JCO.20.03007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078482/
https://www.ncbi.nlm.nih.gov/pubmed/33306425
http://dx.doi.org/10.1200/JCO.20.03007

Ejemplares similares